Navigation Links
Surveyed Oncologists Expect to Prescribe Provenge to about Half of Their Prostate Cancer Patients if the Vaccine is Approved
Date:7/28/2009

WALTHAM, Mass., July 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Dendreon's Provenge receives regulatory approval, surveyed oncologists expect to prescribe Provenge to 54 percent of patients with asymptomatic hormone refractory metastatic prostate cancer. Due to the side effects associated with currently available chemotherapy, most oncologists recommend that men who have stopped responding to hormone therapy wait for the development of symptoms before starting chemotherapy.

The new Physician & Payer Forum report entitled Clinician and Payer Attitudes Toward Emerging Cancer Vaccines for Prostate Cancer, Lung Cancer, and Glioma finds that clinicians are willing to prescribe Provenge to patients in the absence of symptoms. The report also finds that three-quarters of surveyed oncologists and urologists consider Provenge a major breakthrough in the treatment of prostate cancer. Additionally, 89 percent of surveyed urologists expect to prescribe Provenge for prostate cancer.

"Treatment rates for advanced prostate cancer will be boosted by an effective vaccine which also carries a benign side effect profile," said Decision Resources Analyst Marcus Hoyle. "Surveyed clinicians indicate they are very encouraged by the fact that, in a Phase III clinical trial, Provenge demonstrated an improvement in median overall survival in prostate cancer patients."

In addition to Provenge, other therapeutic vaccines in development for cancer include Merck KGaA's Stimuvax for non-small-cell lung cancer and Celldex Therapeutics/Pfizer's CDX-110 for glioblastoma multiforme (glioma). Surveyed experts consider both drugs to be the most promising therapeutic vaccines for the treatment of these two diseases, owing to an impressive effect on overall survival
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibbs Orencia
2. For Treatment of Type 2 Diabetes, 89 Percent of Surveyed Endocrinologists Identify a Need for Additional GLP-1 Analogues and 71 Percent Say the Same About DPP-IV Inhibitors
3. For Treatment of Dyslipidemia, Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials
4. Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting
5. Surveyed Psychiatrists and PCPs Expect to Increase Their First-Line Use of SNRIs Over the Next Two Years for the Treatment of Generalized Anxiety Disorder
6. For Alzheimers Disease, Surveyed Neurologists Identify a Therapys Effect on Cognitive Decline as the Attribute That Most Influences Their Prescribing Decisions
7. For Bipolar Depression, Surveyed Experts Indicate That Current and Emerging Therapies Have No Advantage Over Seroquel in Decreasing the Severity of Symptoms
8. Surveyed Experts Indicate That the Combination of Sutent and Taxol Has Advantages Over the Combination of Avastin and Taxol in the Treatment of Metastatic Triple-Negative Breast Cancer
9. Surveyed Specialists Foresee Greater Use of Parenteral Outpatient Therapy for the Treatment of Osteomyelitis
10. For Atrial Fibrillation, Surveyed Experts Indicate That Multaq, Celivarone and ATI-2042 Have Advantages Over Propafenone in the Maintenance of Normal Sinus Rhythm
11. For Ulcerative Colitis, Surveyed Experts Indicate That Corticosteroids Have Advantages Over Remicade in the Induction of Remission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... After a 13-year absence from active ... to the stage to entertain his many worldwide fans. ... and the successful tour has been steadily expanding since ... Visit Ticketability.com for a large inventory of ... fair prices. , Music fans have had a long ...
(Date:12/19/2014)... News) -- A new study suggests a possible link ... flashes and night sweats -- and higher rates of ... common during menopause, affecting about 60 percent of women. ... menopause, since they then face a higher risk of ... who exhibit moderate or severe menopausal symptoms are more ...
(Date:12/19/2014)... (HealthDay News) -- Prostaglandin analogue eye drops -- a ... risk of vision loss in patients with the eye ... by David Garway-Heath, of the Moorfields Eye Hospital and ... more than 500 people newly diagnosed with open-angle glaucoma ... one of the leading causes of blindness. About ...
(Date:12/17/2014)... Providence, RI (PRWEB) December 17, 2014 ... nationally recognize private practices that have made outstanding ... and in support and progression of private practice ... the American Physical Therapy Association. , On behalf ... DPT, OCS, owner and CEO of Performance accepted ...
(Date:12/17/2014)... Crest Hill, IL (PRWEB) December 17, 2014 ... of 2015 Awards celebrate the best of the best ... States. The award is only given to communities and ... families through the SeniorAdvisor.com site. Of the nearly 100,000 ... with this award. Winners of the SeniorAdvisor.com Best of ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3
... risk of developing leukemia as a side effect of a ... according to a study presented as part of the Late-breaking ... Meeting in Seattle, April 25 - May 2, 2009.Mitoxantrone is ... several forms of advancing MS. It is one of only ...
... manage stress at work and in their homes is ... million National Institutes of Health grant that will also ... reduce employee stress and promote well-being., "We,re seeing that ... that can increase stress and reduce quality of life ...
... related art ROSEMONT, Ill., April 30 Wartime experiences not ... the physicians and medical teams who treat them. As ... orthopaedic surgeons who are caring and have cared for them, ... (AAOS) is opening the call for entries to a unique, ...
... Patients in Many Markets, Dayton , ... Area Quick-Clinic Void with Kroger Partnership, ... HealthLeaders-InterStudy, a leading provider of managed care market intelligence, ... across the country, they have not taken off in the ...
... the immune system attacks the body,s own material just as ... MS for short, is just one such autoimmune disease, and ... 20 to 30 years age group. The disease can have ... attack the central nervous system. It has long been assumed ...
... Inc. today announced that Chris Streng, Vice President, Finance ... been elected to the Codexis Board of Directors, bringing ... Houston, Texas, where he is employed by Shell Downstream ... petrochemical plants in the Shell Group worldwide. He ...
Cached Medicine News:Health News:Risk of Leukemia with Multiple Sclerosis Drug Higher Than Thought 2Health News:Penn State plays integral role in $35 million stress project 2Health News:War and Musculoskeletal Injury Prompt Artistic Expression 2Health News:War and Musculoskeletal Injury Prompt Artistic Expression 3Health News:Physician-Led Quick-Care Clinics Protect Patient Base 2Health News:Physician-Led Quick-Care Clinics Protect Patient Base 3Health News:Gray matter under attack in multiple sclerosis 2Health News:Gray matter under attack in multiple sclerosis 3Health News:Shell Finance Executive Streng Elected to Codexis Board 2
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
(Date:12/17/2014)... 2014 PCCA received the Autism Hope ... ) program seal for best practices in meeting ... medical practices, materials and goods that meet strict ... Children affected by autism often have unique physical ... ingredients found in food and medicine – for ...
(Date:12/15/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ... Vena Cava (IVC) Filters - Global Trends, Estimates and ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior ... US$435 million by 2016. The North America ... global value while Europe claims ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4
Amylase (EPS-G7, kinetics), Wavelength: 405 nm. Linear range; 5-1500 IU/L....
g-GT Liquid Reagent (Kinetic Method). Wavelength: 405 nm. Linear range: 0-200 U/mL. Prepare Working Reagent in the ratio of 5 parts R1 to 1 part of R2, (i.e., 50 mL R1 and 10 mL R2)....
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
... the quantitative determination of alanine ... plasma. Two vials, dry powder ... be purchased separately for conformity ... Wavelength: 340 nm. Linearity: 268 ...
Medicine Products: